GLP-1 Allergic & Injection-Site Reactions (2026)

If you just started Ozempic, Wegovy, Mounjaro or Zepbound and noticed a red, itchy bump where you injected, the question is almost always the same: is this a normal reaction, or a dangerous allergy? The reassuring answer from the trial data and FDA labels is that the two are very different things. Injection-site reactions — redness, itching, a small firm nodule — are local, common-ish, and almost always harmless: in Wegovy's weight-loss trials they occurred in about 1.4% of patients versus 1% on placebo ^[1], and in Zepbound's trials about 6–8% across doses versus 2% on placebo ^[2]. True hypersensitivity — a whole-body allergic reaction, and at the extreme, anaphylaxis or angioedema — is genuinely rare: severe hypersensitivity occurred in only about 0.1% of Zepbound-treated patients in two weight-loss studies ^[2], and anaphylaxis/angioedema appear mainly as uncommon post-marketing reports across the class ^[1][4]. This article lays out the real frequencies, how to tell a benign reaction from an emergency, and why compounded GLP-1s add their own wrinkle. It is educational, not medical advice. For the related question of bruising and rotating sites, see GLP-1 injection bruising and site rotation, and for technique, how to inject a GLP-1 step by step.

The honest summary

• Injection-site reactions are local and usually benign. Redness, itching, swelling, and small firm nodules at the spot you injected. Wegovy trials: ~1.4% vs 1% placebo ^[1]; Zepbound trials: ~6–8% vs 2% placebo ^[2]; Mounjaro placebo-controlled trials: ~3.2% vs 0.4% placebo ^[3]. They typically fade on their own over days.
• True allergy (systemic hypersensitivity) is rare. Severe hypersensitivity was about 0.1% of Zepbound-treated patients in two weight-loss studies ^[2]. Most reactions labeled "hypersensitivity" in trials were mild skin reactions like rash or itching, not anaphylaxis.
• Anaphylaxis and angioedema are rare but real. Both semaglutide and tirzepatide labels list serious hypersensitivity reactions including anaphylaxis and angioedema, reported largely through post-marketing surveillance where exact rates cannot be reliably calculated ^[1][4]. Tirzepatide is contraindicated in anyone with a known serious hypersensitivity to it ^[2].
• Anti-drug antibodies nudge the numbers up. For tirzepatide, injection-site reactions were far more common in patients who developed anti-tirzepatide antibodies (11.3%) than those who did not (1%); hypersensitivity reactions were 6.2% vs 3% ^[2]. Antibodies did not reduce how well the drug worked ^[3].
• Benign vs emergency is about WHERE and HOW FAST. A reaction confined to the injection spot is local. A reaction with hives spreading over the body, swelling of the lips/tongue/throat, trouble breathing, dizziness or fainting within minutes is a medical emergency — call 911.
• Compounded GLP-1s add risk that has nothing to do with the molecule. The FDA has flagged dosing errors and adverse events with compounded semaglutide ^[8], and non-sterile compounding can introduce contamination and infection at the injection site that branded single-use pens largely avoid.

Injection-site reactions: what they are and how common

An injection-site reaction is a local response in the skin and tissue right where the needle went in. Typical features are redness (erythema), itching (pruritus), mild swelling or firmness, a small lump or nodule, and occasionally bruising or tenderness. They are confined to the injection area — they do not spread across the body — and they usually settle over a few days without treatment. They are a recognized, expected part of subcutaneous injectable therapy, not a sign of a dangerous allergy.

The trial numbers are modest. In Wegovy's adult weight-loss program, injection-site reactions (including injection-site pruritus, erythema, inflammation, induration, and irritation) occurred in about 1.4% of Wegovy-treated patients versus 1% on placebo ^[1]. Zepbound's weight-loss studies reported them more often — roughly 6%, 8%, and 8% at the 5 mg, 10 mg, and 15 mg doses versus 2% on placebo ^[2]. Mounjaro's pooled placebo-controlled diabetes trials list injection-site reactions in about 3.2% of patients versus 0.4% on placebo ^[3]. Ozempic's common-reaction profile similarly puts injection-site reactions around the low single digits ^[4]. Across all of these, the reactions described in the tables are local and skin-level, not systemic.

True allergy: hypersensitivity, anaphylaxis, and angioedema

A true allergic reaction is the immune system reacting to the drug systemically — beyond the injection site. It can range from a widespread rash, hives (urticaria), or generalized itching, up to anaphylaxis (a rapid, life-threatening reaction with airway, breathing, and circulation involvement) and angioedema (deep swelling, often of the lips, tongue, face, or throat). These are categorically different from a red bump at the injection site, and they are rare.

How rare? In a pool of two Zepbound weight-loss studies, 0.1% of Zepbound-treated patients had severe hypersensitivity reactions versus none on placebo ^[2] — and the label notes that the majority of hypersensitivity reactions in trials were skin reactions such as rash and itching, not anaphylaxis. Both the semaglutide labels (Ozempic, Wegovy) and the tirzepatide labels (Mounjaro, Zepbound) carry warnings that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported ^[1][2][3][4]. Most of those serious reports come from post-marketing surveillance — meaning they were reported voluntarily after approval, from a population of uncertain size, so the labels explicitly state it is not always possible to reliably estimate their frequency ^[4]. Tirzepatide is formally contraindicated in anyone with a known serious hypersensitivity to it ^[2].

Case reports fill in the texture of what milder, delayed allergy can look like. Dermatology literature documents a semaglutide-induced fixed drug eruption — recurrent well-defined patches appearing at the same sites after dosing ^[5] — and a delayed-type hypersensitivity reaction to liraglutide in a patient who then tolerated semaglutide without issue ^[6]. Pharmacovigilance analyses of the FDA Adverse Event Reporting System (FAERS) for tirzepatide have catalogued injection-site and hypersensitivity signals alongside the far more common gastrointestinal events ^[7]. The throughline: serious whole-body allergy to GLP-1s is uncommon, and reacting to one agent does not automatically mean you will react to another.

Cross-reactivity: does an allergy to one GLP-1 mean allergy to all?

Not necessarily. GLP-1 receptor agonists are not identical molecules — semaglutide and liraglutide are peptide analogs of human GLP-1, while tirzepatide is a dual GIP/GLP-1 agonist with a distinct structure, and each product has different excipients. A documented case of delayed hypersensitivity to liraglutide with subsequent tolerance of semaglutide shows that switching agents can sometimes work ^[6]. That said, cross-reactivity is unpredictable and switching after a true allergic reaction should only be done under medical and ideally allergy-specialist supervision, sometimes with skin testing — never by self-experimentation. If your reaction was anaphylaxis or angioedema, the default is to avoid the class until an allergist clears a specific alternative.

Benign or emergency? How to tell

The single most useful distinction is where the reaction is and how fast it moves. A reaction that stays put at the injection site and builds slowly over hours is local and almost always benign. A reaction that spreads across the body and escalates within minutes to an hour — especially with breathing or swallowing involvement — is the pattern of a systemic allergic emergency.

Compounded vs branded: an extra layer of reaction risk

Reaction risk is not only about the active molecule — it is also about what else is in the vial and how it was made. FDA-approved branded products (Ozempic, Wegovy, Mounjaro, Zepbound) come in single-use pens or tightly specified formulations that undergo premarket review for quality and sterility. Compounded semaglutide and tirzepatide — made by compounding pharmacies, often in multi-dose vials — do not undergo that FDA premarket review, and they introduce variables that can drive injection-site and other reactions independent of the drug itself: different salt forms or excipients, varying concentrations, and the possibility of contamination in non-sterile preparation.

The FDA has issued an alert about dosing errors associated with compounded injectable semaglutide, citing reports of adverse events — some requiring hospitalization — tied to patients drawing up the wrong amount from vials and syringes, with reported overdoses of 5 to 20 times the intended dose ^[8]. Beyond systemic overdose effects, multi-dose vials and self-drawn syringes carry a higher local infection and injection-site-reaction risk than sealed single-use pens. If you experience injection-site reactions on a compounded product, the formulation and sterility — not just the molecule — are worth discussing with your prescriber.

Practical takeaways

• A red, itchy bump at the injection site is almost always benign. It is a local reaction, not an allergy to the drug. Rotate sites, let the pen reach room temperature, and it usually fades in days.
• Learn the emergency signs cold. Spreading hives, swelling of lips/tongue/throat, trouble breathing, dizziness or fainting — especially within minutes — mean stop the drug and call 911.
• True allergy is rare — on the order of 0.1% severe hypersensitivity in trial data ^[2] — but it is real, and anaphylaxis/angioedema are listed warnings for the whole class ^[1][4].
• Reacting to one GLP-1 does not guarantee you'll react to another ^[6], but any switch after a true allergic reaction belongs to your clinician or an allergist, not to self-experimentation.
• If you use a compounded product, factor in formulation and sterility. The FDA has flagged dosing errors and adverse events with compounded semaglutide ^[8].
• This is educational, not medical advice. Bring any reaction — local or systemic — to your prescriber, and treat breathing/swelling/whole-body symptoms as an emergency.

This article is educational and is not medical advice. Frequencies are taken from the current FDA prescribing information for Wegovy, Zepbound, Mounjaro, and Ozempic (verified against DailyMed and accessdata.fda.gov), peer-reviewed case reports and pharmacovigilance analyses indexed in PubMed, and an FDA compounding alert — each verified against the live source on June 5, 2026. If you have signs of a serious allergic reaction (spreading hives, swelling of the lips/tongue/throat, trouble breathing, dizziness or fainting), seek emergency care immediately.